CONTEXT: The European Association of Urology (EAU) panel on Non-muscle-invasive Bladder Cancer (NMIBC) released an updated version of the guidelines on Non-muscle-invasive Bladder Cancer. OBJECTIVE: To present the 2016 EAU guidelines on NMIBC. EVIDENCE ACQUISITION: A broad and comprehensive scoping exercise covering all areas of the NMIBC guidelines published between April 1, 2014, and May 31, 2015, was performed. Databases covered by the search included Medline, Embase, and the Cochrane Libraries. Previous guidelines were updated, and levels of evidence and grades of recommendation were assigned. EVIDENCE SYNTHESIS: Tumours staged as TaT1 or carcinoma in situ (CIS) are grouped as NMIBC. Diagnosis depends on cystoscopy and histologic evaluation of the tissue obtained by transurethral resection of the bladder (TURB) in papillary tumours or by multiple bladder biopsies in CIS. In papillary lesions, a complete TURB is essential for the patient's prognosis. If the initial resection is incomplete, there is no muscle in the specimen, or a high-grade or T1 tumour is detected, a second TURB should be performed within 2-6 wk. The risks of both recurrence and progression may be estimated for individual patients using the European Organisation for Research and Treatment of Cancer (EORTC) scoring system and risk tables. The stratification of patients into low-, intermediate-, and high-risk groups is pivotal to recommending adjuvant treatment. For patients with a low-risk tumour and intermediate-risk patients at a lower risk of recurrence, one immediate instillation of chemotherapy is recommended. Patients with an intermediate-risk tumour should receive 1 yr of full-dose bacillus Calmette-Guérin (BCG) intravesical immunotherapy or instillations of chemotherapy for a maximum of 1 yr. In patients with high-risk tumours, full-dose intravesical BCG for 1-3 yr is indicated. In patients at highest risk of tumour progression, immediate radical cystectomy (RC) should be considered. RC is recommended in BCG-refractory tumours. The long version of the guidelines is available at the EAU Web site (www.uroweb.org/guidelines). CONCLUSIONS: These abridged EAU guidelines present updated information on the diagnosis and treatment of NMIBC for incorporation into clinical practice. PATIENT SUMMARY: The European Association of Urology has released updated guidelines on Non-muscle-invasive Bladder Cancer (NMIBC). Stratification of patients into low-, intermediate-, and high-risk groups is essential for decisions about adjuvant intravesical instillations. Risk tables can be used to estimate risks of recurrence and progression. Radical cystectomy should be considered only in case of failure of instillations or in NMIBC with the highest risk of progression.

AP HP Hôpital La Pitié Salpétrière Service d'Urologie Paris France; UPMC University Paris 06 GRC5 ONCOTYPE Uro Institut Universitaire de Cancérologie Paris France

Department of Pathology Hôpital La Pitié Salpétrière UPMC Paris France

Department of Surgery and Cancer Imperial College London UK; Department of Urology Lister Hospital East and North Hertfordshire NHS Trust Stevenage UK

Department of Surgical Oncology Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam The Netherlands

Department of Urology Caritas St Josef Medical Centre University of Regensburg Regensburg Germany

Department of Urology Fundació Puigvert Universidad Autónoma de Barcelona Barcelona Spain

Department of Urology General University Hospital 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Urology HELIOS Agnes Karll Krankenhaus Bad Schwartau Germany

Department of Urology Hospital Motol 2nd Faculty of Medicine Charles University Praha Czech Republic

Department of Urology Hospital Universitario Fundación Alcorcón Madrid Spain

Department of Urology Hyvinkää Hospital Hyvinkää Finland

Department of Urology Medical University of Graz Graz Austria

European Association of Urology Guidelines Office Brussels Belgium

Medical University of Vienna Vienna General Hospital Vienna Austria

Komentář v

Eur Urol. 2017 Jun;71(6):e173-e174. doi: 10.1016/j.eururo.2016.11.029. PubMed

Komentář v

Eur Urol. 2017 Jun;71(6):e171-e172. doi: 10.1016/j.eururo.2016.11.030. PubMed

Citace poskytuje Crossref.org

Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer

Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate

Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex

Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer

Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis

SIU-ICUD on bladder cancer: pathology

A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens

An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer